Join Us →
  • ID IND
  • EN ENG
IASMED Indonesian Clincial Trial

Your Gateway to Southeast
Asia’s Clinical Research Hub

Harnessing Indonesia’s unmatched diversity and data to accelerate breakthrough clinical research that transforms lives.

Learn More Collaborate with Us →

281M+

Population

Tooltips Referring to Badan Pusat Statistik – June 2024

17,000+

Islands across the nation

Tooltips Referring to Badan Informasi Geospasial – Desember 2024

163

Approved clinical studies

Tooltips Cumulative data, referring to BPOM published database

27

Clinical Research Unit (CRU)

Tooltips Not including re-certification; referring to IASMED internal database

5,455

GCP-certified professionals

Tooltips Cumulative data, referring to IASMED internal database
Country

Country landscape

Read about Country Landscape Indonesia.

Regulation

Regulation

Read about Regulation in Indonesia.

×

Country Landscape

Indonesia, with over 281 million people and 1,200+ ethnic groups across 17,000+ islands, holds immense potential as a clinical trial site. With its vast, diverse patient pool and growing readiness, the country is now better positioned than ever.

Clinical trial approvals—drugs, cosmetics, and supplements by Indonesian FDA, and medical devices by the Ministry of Health—have reached 163. Though still growing, Indonesia is on track to become a leading clinical trial hub in Southeast Asia within 5–10 years.

References
¹ Badan Pusat Statistik – June 2024
² Badan Pusat Statistik – December 2024
³ Badan Informasi Geospasial – December 2024
⁴ Badan POM – Informasi Uji Klinik Obat
×

Regulation

The Indonesian government is steadily improving the clinical research environment. A key update is the revised Material Transfer Agreement (MTA), now with clearer timelines and criteria — a long-awaited change for Sponsors.

The Ministry of Health has formed the Indonesia Clinical Research Center (INA-CRC) to connect Sponsors with stakeholders, assist administrative processes, and ensure GCP compliance. It also manages the Indonesia Clinical Research Registry (INA-CRR) to boost research transparency.

Another key initiative underway is the Central Ethics Committee (KEEPKN), which aims to centralize ethics reviews for multicenter studies — marking Indonesia’s rising readiness in clinical research.

References
¹ Ministry of Health Indonesia – Material Transfer Agreement Revision, 2024
² Ministry of Health Indonesia – INA-CRC Establishment Decree, 2023
³ INA-CRR: Indonesia Clinical Research Registry Official Portal, 2024
⁴ Preparation Brief of KEEPKN – Coordinated by MoH and National Ethics Forum, 2024

Indonesian Clinical Trial
Service Providers

Explore the available network of top organizations and service providers committed to enhancing clinical research in Indonesia.

  • IQVIA
  • Syneos Health
  • Parexel
  • Oxford University Clinical Research Unit
  • Tigermed
  • Prodia the CRO
  • Equilab International
  • PharmaMetrics Lab
  • Hayya Life Science
  • Corpora Science
  • Increase Laboratorium Indonesia
  • Labdha Teknika Nusantara
  • Kedata Indonesia Digital
  • Prodia Laboratory
  • Increase Laboratorium Indonesia
  • Equilab International
  • Zuellig Pharma

Clinical Research Units
Across Indonesia

Indonesia possesses well-established clinical research units that are fully equipped to conduct studies adhering to the highest standards of scientific rigor and ethical compliance.

Search

Collaborate with us to advance
clinical trials in Indonesia!

Contact Us →